Abstract
Head and neck squamous cell carcinomas (HNSCC) are loco-regionally aggressive tumors that often lead to debilitating changes in appearance, speech, swallowing and respiratory function in patients. It is therefore critical to develop novel targeted treatment strategies that can effectively target multiple components within the tumor microenvironment. In this regard, there has been an increased recognition of the role of neural signaling networks as mediators of disease progression in HNSCC. Here, we summarize the current knowledge on the mechanisms of adrenergic signaling in HNSCC specifically focusing on neurovascular crosstalk and the potential of targeting the adrenergic-angiogenic axis through repurposing of FDA-approved drugs against HNSCC.
Highlights
Head and neck squamous cell carcinomas (HNSCC) are loco-regionally aggressive tumors that result in debilitating functional and esthetic sequelae in approximately half a million individuals worldwide [1, 2]
We summarize the current knowledge on the neurovascular talk in HNSCC focusing on the adrenergic signaling within the head and neck tumor microenvironment
Neuronal programming and neurovascular interactions represent relatively understudied mechanisms that contribute to malignant progression in HNSCC
Summary
Head and neck squamous cell carcinomas (HNSCC) are loco-regionally aggressive tumors that result in debilitating functional and esthetic sequelae in approximately half a million individuals worldwide [1, 2]. Given the significant costs associated with drug development, an informed approach focused on identifying and evaluating existing FDA-approved agents that target critical pathways implicated in development, progression or treatment resistance in HNSCC would be beneficial. In this context, there has been an increased recognition of the role of neural signaling networks as mediators of disease progression and therapeutic resistance in several solid tumors including HNSCC [6,7,8]. We summarize the current knowledge on the neurovascular talk in HNSCC focusing on the adrenergic signaling within the head and neck tumor microenvironment. The rationale for targeting the adrenergic-angiogenic axis through repurposing of FDA-approved neuroscience drugs against HNSCC is presented
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
